Legal & General Group
RGC icon

Legal & General Group’s Regencell Bioscience RGC Stock Holding History

Legal & General Group’s Portfolio RGC Stock Details RGC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$779K Buy
128,000
+118,097
+1,193% +$2.84M ﹤0.01% 2270
2026
Q1 		$252K Buy
+9,903
New +$280K ﹤0.01% 2498

Other funds holding RGC

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return
Amundi
Amundi Paris, France $416B AUM 44.19% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
QC
Quadrature Capital London, United Kingdom $11.7B AUM 87.29% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
Squarepoint
Squarepoint New York $90.5B AUM 33.95% 1-Year Est. Return
FRM
Fox Run Management Greenwich, Connecticut $603M AUM 32% 1-Year Est. Return

Legal & General Group's RGC Position: Q2 2026 in Review

Legal & General Group increased its Regencell Bioscience (RGC) stake by 1,193% in Q2 2026, buying an estimated $2.84M and bringing the position to 128,000 shares worth $779K. The position accounts for ﹤0.01% of the portfolio, ranked #2270.

Legal & General Group first reported a position in RGC in Q1 2026 and has held it in 2 quarters since. 35 funds tracked by Wall St. Rank hold RGC as of Q2 2026.

  • Legal & General Group held 128,000 shares of Regencell Bioscience worth $779K as of Q2 2026.
  • Legal & General Group bought 118,097 Regencell Bioscience shares in Q2 2026, an estimated $2.84M.
  • Regencell Bioscience made up ﹤0.01% of Legal & General Group's portfolio in Q2 2026, its #2270 holding.
  • Legal & General Group first reported a position in Regencell Bioscience in Q1 2026 and has held it in 2 quarters since.
  • 35 funds tracked by Wall St. Rank held Regencell Bioscience as of Q2 2026.

Based on Legal & General Group's 13F filing for Q2 2026, filed 14 Aug 2026.